Phenotypic modulation of macrophages in response to plaque lipids

Current Opinion in Lipidology

Volumn 22, Issue 5, 2011, Pages 335-342

  Adamson, Samantha ^a   Leitinger, Norbert ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

atherosclerosis; inflammation; macrophages; oxidized lipids

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ADENOSINE; ADIPONECTIN; CHOLESTEROL; CHOLESTEROL ESTER; FATTY ACID; FINGOLIMOD; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; LYSOPHOSPHOLIPID; OMEGA 3 FATTY ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; OXYSTEROL; PALMITIC ACID; PATTERN RECOGNITION RECEPTOR; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; PROTEIN; REACTIVE OXYGEN METABOLITE; RESOLVIN; SPHINGOSINE 1 PHOSPHATE; TACROLIMUS; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL POLARITY; CRYSTALLIZATION; EXERCISE; FOAM CELL; GENE EXPRESSION; GENE INTERACTION; HUMAN; INFLAMMATION; LIPID OXIDATION; MACROPHAGE; MACROPHAGE FUNCTION; MEDIATOR RELEASE; NITROSYLATION; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; UPREGULATION;

ANIMALS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; LIPID METABOLISM; MACROPHAGES; OXIDATION-REDUCTION;

MUS;

EID: 80052757406     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32834a97e4     Document Type: Review

References (96)

1. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27:451-483.
2. Bystrom J, Evans I, Newson J, et al. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood 2008; 112:4117-4127.
3. Kadl A, Meher AK, Sharma PR, et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res 2010; 107:737-746.
4. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145:341-355.
5. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 2009; 29:1419-1423.
6. Shimada K. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ J 2009; 73:994-1001.
7. Johnson JL, Newby AC. Macrophage heterogeneity in atherosclerotic plaques. Curr Opin Lipidol 2009; 20:370-378.
8. Waldo SW, Li Y, Buono C, et al. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008; 172:1112-1126. (Pubitemid 351520007)
9. Bouhlel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007; 6:137-143. (Pubitemid 47189091)
10. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117:195-205. (Pubitemid 46048466)
11. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117:185-194. (Pubitemid 46048465)
12. Devaraj S, Jialal I. C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol 2011; 31:1397-1402.
13. Yakeu G, Butcher L, Isa S, et al. Low-intensity exercise enhances expression of markers of alternative activation in circulating leukocytes: roles of PPARgamma and Th2 cytokines. Atherosclerosis 2010; 212:668-673.
14. Boyle JJ, Harrington HA, Piper E, et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol 2009; 174:1097-1108.
15. Sindrilaru A, Peters T, Wieschalka S, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest 2011; 121:985-997.
16. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31:986-1000.
17. Davies SS, Roberts LJ. F2-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med 2011; 50:559-566.
18. Shibata N, Glass CK. Macrophages, oxysterols and atherosclerosis. Circ J 2010; 74:2045-2051.
19. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11:155-161.
20. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 2010; 12:467-482.
21. van Tits LJ, Stienstra R, van Lent PL, et al. Oxidized LDL enhances proinflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2. Atherosclerosis 2011; 214:345-349.
22. Bae YS, Lee JH, Choi SH, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4-and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res 2009; 104:210-218, 21p.
23. Chavez-Sanchez L, Madrid-Miller A, Chavez-Rueda K, et al. Activation of TLR2 and TLR4 by minimally modified low-density lipoprotein in human macrophages and monocytes triggers the inflammatory response. Hum Immunol 2010; 71:737-744.
24. Wiesner P, Choi SH, Almazan F, et al. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappa B and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circ Res 2010; 107:56-65.
25. Fang L, Harkewicz R, Hartvigsen K, et al. Oxidized cholesteryl esters and phospholipids in zebrafish larvae fed a high cholesterol diet: macrophage binding and activation. J Biol Chem 2010; 285:32343-32351.
26. Forlenza M, Fink IR, Raes G, Wiegertjes GF. Heterogeneity of macrophage activation in fish. Dev Comp Immunol 2011 [Epub ahead of print].
27. Walton KA, Hsieh X, Gharavi N, et al. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8: a role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem 2003; 278:29661-29666. (Pubitemid 36962351)
28. Imai Y, Kuba K, Neely GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133:235-249. (Pubitemid 351512299)
29. Cruz D, Watson AD, Miller CS, et al. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest 2008; 118:2917-2928.
30. Oskolkova OV, Afonyushkin T, Preinerstorfer B, et al. Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. J Immunol 2010; 185:7706-7712.
31. Erridge C, Webb DJ, Spickett CM. Toll-like receptor 4 signalling is neither sufficient nor required for oxidised phospholipid mediated induction of interleukin-expression. Atherosclerosis 2007; 193:77-85. (Pubitemid 46776713)
32. vonSchlieffen E, Oskolkova OV, Schabbauer G, et al. Multihit inhibition of circulating and cell-associated components of the toll-like receptor 4 pathway by oxidized phospholipids. Arterioscler Thromb Vasc Biol 2009; 29:356-362.
33. Kuhn AM, Tzieply N, Schmidt MV, et al. Antioxidant signaling via Nrf2 counteracts lipopolysaccharide-mediated inflammatory responses in foam cell macrophages. Free Radic Biol Med 2011; 50:1382-1391.
34. Freigang S, Ampenberger F, Spohn G, et al. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol 2011; 41:2040-2051.
35. Sussan TE, Jun J, Thimmulappa R, et al. Disruption of Nrf2, a key inducer of antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice. PLoS ONE 2008; 3:e3791.
36. Barajas B, Che N, Yin F, et al. NF-E2-related factor 2 promotes atherosclerosis by effects on plasma lipoproteins and cholesterol transport that overshadow antioxidant protection. Arterioscler Thromb Vasc Biol 2011; 31:58-66.
37. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464:1357-1361.
38. Rajamaki K, Lappalainen J, Oorni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 2010; 5:e11765.
39. Leitinger N. Cholesteryl ester oxidation products in atherosclerosis. Mol Aspects Med 2003; 24:239-250. (Pubitemid 36945024)
40. Harkewicz R, Hartvigsen K, Almazan F, et al. Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized low density lipoprotein. J Biol Chem 2008; 283:10241-10251.
41. Huber J, Boechzelt H, Karten B, et al. Oxidized cholesteryl linoleates stimulate endothelial cells to bind monocytes via the extracellular signal-regulated kinase 1/2 pathway. Arterioscler Thromb Vasc Biol 2002; 22:581-586. (Pubitemid 34408737)
42. Huang Z, Li W, Wang R, et al. 7-ketocholesteryl-9-carboxynonanoate induced nuclear factor-kappa B activation in J774A.1 macrophages. Life Sci 2010; 87:651-657.
43. Choi SH, Harkewicz R, Lee JH, et al. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res 2009; 104:1355-1363.
44. Sottero B, Gamba P, Longhi M, et al. Expression and synthesis of TGFbeta1 is induced in macrophages by 9-oxononanoyl cholesterol, a major cholesteryl ester oxidation product. Biofactors 2005; 24:209-216. (Pubitemid 41750544)
45. Jedidi I, Couturier M, Therond P, et al. Cholesteryl ester hydroperoxides increase macrophage CD36 gene expression via PPARalpha. Biochem Biophys Res Commun 2006; 351:733-738. (Pubitemid 44780858)
46. Kar NS, Ashraf MZ, Valiyaveettil M, Podrez EA. Mapping and characterization of the binding site for specific oxidized phospholipids and oxidized low density lipoprotein of scavenger receptor CD36. J Biol Chem 2008; 283:8765-8771.
47. Yakubenko VP, Bhattacharjee A, Pluskota E, Cathcart MK. alphaMbeta integrin activation prevents alternative activation of human and murine macrophages and impedes foam cell formation. Circ Res 2011; 108:544-554.
48. Chen T, Huang Z, Wang L, et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res 2009; 83:131-139.
49. Leonarduzzi G, Gamba P, Sottero B, et al. Oxysterol-induced up-regulation of MCP-1 expression and synthesis in macrophage cells. Free Radic Biol Med 2005; 39:1152-1161. (Pubitemid 41407710)
50. Leonarduzzi G, Gargiulo S, Gamba P, et al. Molecular signaling operated by a diet-compatible mixture of oxysterols in up-regulating CD36 receptor in CD68 positive cells. Mol Nutr Food Res 2010; 54 (Suppl 1):S31-S41.
51. Boyanovsky BB, Li X, Shridas P, et al. Bioactive products generated by group V sPLA(2) hydrolysis of LDL activate macrophages to secrete pro-inflammatory cytokines. Cytokine 2010; 50:50-57.
52. Lahdesmaki K, Plihtari R, Soininen P, et al. Phospholipase A(2)-modified LDL particles retain the generated hydrolytic products and are more atherogenic at acidic pH. Atherosclerosis 2009; 207:352-359.
53. Peter C, Waibel M, Radu CG, et al. Migration to apoptotic 'find-me' signals is mediated via the phagocyte receptor G2A. J Biol Chem 2008; 283:5296-5305.
54. Wang L, Radu CG, Yang LV, et al. Lysophosphatidylcholine-induced surface redistribution regulates signaling of the murine G protein-coupled receptor G2A. Mol Biol Cell 2005; 16:2234-2247. (Pubitemid 40632208)
55. Yang LV, Radu CG, Wang L, et al. Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood 2005; 105:1127-1134. (Pubitemid 40170885)
56. Obinata H, Hattori T, Nakane S, et al. Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G proteincoupled receptor G2A. J Biol Chem 2005; 280:40676-40683. (Pubitemid 41780559)
57. Ogawa A, Obinata H, Hattori T, et al. Identification and analysis of two splice variants of human G2A generated by alternative splicing. J Pharmacol Exp Ther 2010; 332:469-478.
58. Bolick DT, Skaflen MD, Johnson LE, et al. G2A deficiency in mice promotes macrophage activation and atherosclerosis. Circ Res 2009; 104:318-327.
59. Parks BW, Srivastava R, Yu S, Kabarowski JH. ApoE-dependent modulation of HDL and atherosclerosis by G2A in LDL receptor-deficient mice independent of bone marrow-derived cells. Arterioscler Thromb Vasc Biol 2009; 29:539-547.
60. Parks BW, Lusis AJ, Kabarowski JH. Loss of the lysophosphatidylcholine effector, G2A, ameliorates aortic atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2006; 26:2703-2709.
61. Ishiyama J, Taguchi R, Yamamoto A, Murakami K. Palmitic acid enhances lectin-like oxidized LDL receptor (LOX-1) expression and promotes uptake of oxidized LDL in macrophage cells. Atherosclerosis 2010; 209:118-124.
62. Dasu MR, Jialal I. Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors. Am J Physiol Endocrinol Metab 2011; 300:E145-E154.
63. Joosten LA, Netea MG, Mylona E, et al. Engagement of fatty acids with Tolllike receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010; 62:3237-3248.
64. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acidinduced insulin resistance. J Clin Invest 2006; 116:3015-3025. (Pubitemid 44684486)
65. Erridge C, Samani NJ. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler Thromb Vasc Biol 2009; 29:1944-1949.
66. Bochkov VN, Leitinger N. Anti-inflammatory properties of lipid oxidation products. J Mol Med 2003; 81:613-626. (Pubitemid 37357676)
67. Ishiyama J, Taguchi R, Akasaka Y, et al. Unsaturated FAs prevent palmitateinduced LOX-1 induction via inhibition of ER stress in macrophages. J Lipid Res 2011; 52:299-307.
68. Coleman SL, Park YK, Lee JY. Unsaturated fatty acids repress the expression of adipocyte fatty acid binding protein via the modulation of histone deacetylation in RAW 264.7 macrophages. Eur J Nutr 2010 [Epub ahead of print].
69. McClelland S, Cox C, O'Connor R, et al. Conjugated linoleic acid suppresses the migratory and inflammatory phenotype of the monocyte/macrophage cell. Atherosclerosis 2010; 211:96-102.
70. Khoo NK, Freeman BA. Electrophilic nitro-fatty acids: anti-inflammatory mediators in the vascular compartment. Curr Opin Pharmacol 2010; 10:179-184.
71. Kansanen E, Bonacci G, Schopfer FJ, et al. Electrophilic nitro-fatty acids activate NRF2 by a KEAP1 cysteine 151-independent mechanism. J Biol Chem 2011; 286:14019-14027.
72. Tsujita T, Li L, Nakajima H, et al. Nitro-fatty acids and cyclopentenone prostaglandins share strategies to activate the Keap1-Nrf2 system: a study using green fluorescent protein transgenic zebrafish. Genes Cells 2011; 16:46-57.
73. Schopfer FJ, Cole MP, Groeger AL, et al. Covalent peroxisome proliferatoractivated receptor gamma adduction by nitro-fatty acids: selective ligand activity and antidiabetic signaling actions. J Biol Chem 2010; 285:12321-12333.
74. Borniquel S, Jansson EA, Cole MP, et al. Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease. Free Radic Biol Med 2010; 48:499-505.
75. Rudolph V, Rudolph TK, Schopfer FJ, et al. Endogenous generation and protective effects of nitro-fatty acids in a murine model of focal cardiac ischaemia and reperfusion. Cardiovasc Res 2010; 85:155-166.
76. Rudolph TK, Rudolph V, Edreira MM, et al. Nitro-fatty acids reduce atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2010; 30:938-945.
77. Cawood AL, Ding R, Napper FL, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010; 212: 252-259.
78. Li S, Sun Y, Liang CP, et al. Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ Res 2009; 105:1072-1082.
79. Groeger AL, Cipollina C, Cole MP, et al. Cyclooxygenase-2 generates antiinflammatory mediators from omega-3 fatty acids. Nat Chem Biol 2010; 6:433-441.
80. Serhan CN, Yang R, Martinod K, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206:15-23.
81. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010; 107:1170-1184.
82. Ho KJ, Spite M, Owens CD, et al. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol 2010; 177:2116-2123.
83. Merched AJ, Ko K, Gotlinger KH, et al. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008; 22:3595-3606.
84. Hughes JE, Srinivasan S, Lynch KR, et al. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res 2008; 102:950-958. (Pubitemid 351591554)
85. Sato K, Okajima F. Role of sphingosine 1-phosphate in antiatherogenic actions of high-density lipoprotein. World J Biol Chem 2010; 1:327-337.
86. Wang F, Okamoto Y, Inoki I, et al. Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice. J Clin Invest 2010; 120:3979-3995.
87. Skoura A, Michaud J, Im DS, et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31:81-85.
88. Khallou-Laschet J, Varthaman A, Fornasa G, et al. Macrophage plasticity in experimental atherosclerosis. PLoS ONE 2010; 5:e8852.
89. Feig JE, Parathath S, Rong JX, et al. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 2011; 123:989-998.
90. Feig JE, Rong JX, Shamir R, et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocytederived cells. Proc Natl Acad Sci USA 2011; 108:7166-7171.
91. Lovren F, Pan Y, Quan A, et al. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol 2010; 299:H656-H663.
92. Bai L, Gabriels K, Wijnands E, et al. Low-but not high-dose FK506 treatment confers atheroprotection due to alternative macrophage activation and unaffected cholesterol levels. Thromb Haemost 2010; 104:143-150.
93. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 115:501-508. (Pubitemid 46188244)
94. Shin S, Moon S, Park Y, et al. Role of cordycepin and adenosine on the phenotypic switch of macrophages via induced anti-inflammatory cytokines. Immune Netw 2009; 9:255-264.
95. Lutgens E, Lievens D, Beckers L, et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207:391-404.
96. Birnbaum Y, Ye Y, Lin Y, et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 2006; 114:929-935. (Pubitemid 44337136)